ProQR Therapeutics NV:初步Ax-0810数据显示给药四周后无安全性信号,药代动力学与非临床数据一致

美股速递
Jan 08

ProQR Therapeutics NV近日公布其候选药物Ax-0810的初期临床研究结果。数据显示,在为期四周的给药周期后,未观察到任何安全性警示信号。同时,该药物的药代动力学特征与此前的非临床研究数据高度吻合,进一步验证了其可控的代谢特性和潜在的治疗窗口。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10